<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874806</url>
  </required_header>
  <id_info>
    <org_study_id>HM20014803</org_study_id>
    <nct_id>NCT03874806</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block</brief_title>
  <official_title>Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block: a Comparison of Bolus Dosing and Continuous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this study are as follows:

        1. to confirm the safe dosing of ropivacaine for the erector spinae plane block

        2. develop a pharmacokinetic profile of the erector spinae plane block, which will help
           demonstrate how quickly and how closely toxic levels are reached when a routine dose of
           ropivacaine is given for this nerve block

        3. assess numbness created by the erector spinae block when routine doses are administered
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Did not receive funding
  </why_stopped>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 hours</time_frame>
    <description>The maximum concentration of serum ropivacaine after pre-determined dose is delivered through the ESP nerve catheter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>28 hours</time_frame>
    <description>The time elapsed from initial ropivacaine administration to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area of analgesia</measure>
    <time_frame>4 hours</time_frame>
    <description>The area of numbness experienced in the chest wall; measured using a pinprick test and documented on a cartoon map showing a chest wall and dermatomal borders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>4 hours</time_frame>
    <description>The duration of numbness to the chest wall; start time will be when the local anesthetic bolus is given, and end time will be when the participant reports the resolution of chest wall numbness</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Pain, Chest</condition>
  <arm_group>
    <arm_group_label>single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>local anesthetic is delivered as a single bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>local anesthetic is delivered as a continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.25%-NaCl 0.9% Injectable Solution</intervention_name>
    <description>0.25% ropivacaine administered through a nerve catheter</description>
    <arm_group_label>single</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.2%-NaCl 0.9% Injectable Solution</intervention_name>
    <description>0.2% ropivacaine administered through a nerve catheter</description>
    <arm_group_label>continuous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant's age is greater than 18 years

          2. Participant is undergoing a primary coronary artery bypass grafting surgery or heart
             valve replacement that requires a midline sternotomy incision

          3. Participant's surgery is being performed by Dr. Vig Kasirajan

        Exclusion Criteria:

          1. Diagnosis of cirrhosis, hepatitis, primary sclerosing cholangitis

          2. Abnormal liver function tests demonstrated by lab results

          3. Allergy to lidocaine, ropivacaine, or midazolam

          4. Morbid obesity, defined as body mass index greater than 40

          5. Existing skin neuropathy on the chest or back

          6. Body weight less than 50 kg

          7. Participant is not able to provide verbal feedback, such as when the participant
             develops altered mental status or requires prolonged mechanical ventilation and
             sedation

          8. Participant remains intubated on post-operative day 1

          9. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryant Tran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03874806/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

